参考文献/References:
[1] de la Monte SM,Wands JR.Alzheimer's disease is type 3 diabetes-evidence reviewed[J].J Diabetes Sci Technol,2008,2(6):1101-1113.
[2] Prince M,Bryce R,Albanese E,et al.The global prevalence of dementia: a systematic review and metaanalysis[J].Alzheimers Dement,2013,9(1):63-75.e2.
[3] Ott A,Stolk RP,Van Harskamp F,et al.Diabetes mellitus and the risk of dementia: The Rotterdam Study[J].Neurology,1999,53(9):1937-1942.
[4] Luchsinger JA,Reitz C,Honig LS,et al.Aggregation of vascular risk factors and risk of incident Alzheimer disease[J].Neurology,2005,65(4):545-551.
[5] Talbot K,Wang HY,Kazi H,et al.Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline[J].J Clin Invest,2012,122(4):1316-1338.
[6] Biessels GJ,Staekenborg S,Brunner E,et al.Risk of dementia in diabetes mellitus: a systematic review[J].Lancet Neurol,2006,5(1):64-74.
[7] Centres for Disease Control and Prevention[J].National Diabetes Fact Sheet,2011, http://www.cdc.gov/ diabetes/ pubs/pdf/ndfs_2011.pdf.2013(accessed June 23, 2013).
[8] Janson J,Laedtke T,Parisi JE.et al. Increased risk of type 2 diabetes in Alzheimer disease[J].Diabetes, 2004, 53(2):474-481.
[9] Roberts RO,Knopman DS,Geda YE,et al.Association of diabetes with amnestic and nonamnestic mild cognitive?impairment[J].Alzheimers Dement,2014,10(1):18-26.
[10] Sanz CM,Hanaire H,Vellas BJ,et al.Diabetes mellitus as a modulator of functional impairment and decline in Alzheimer's disease. The Real.FR cohort[J].Diabet Med,2012,29(4):541-548.
[11] Liu CC,Zhao N,Yamaguchi Y,et al.Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease[J].Sci Transl Med,2016,8(332):332ra44.
[12] Fischer R,Maier O.Interrelation of oxidative stress and inflammation in neurodegenerative disease:role of TNF[Z],2015:610813.
[13] De Felice FG,Lourenco MV,Ferreira ST.How does brain insulin resistance develop in Alzheimer's disease? [J].Alzheimer's Dement, 2014,10(1 Suppl):S26-S32.
[14] Cai ZY,Xiao M,Chang LY,et al.Role of insulin resistance in Alzheimer's disease[J].Metab Brain Dis,2015,30(4):839-851.
[15] Moloney AM,Griffin RJ,Timmons SA,et al.Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling[J].Neurobiol Aging,2010,31(2):224-243.
[16] Plum L,Schubert M,Brüning JC.The role of insulin receptor signaling in the brain[J].Trends Endocrinol Metab,2005,16(2):59-65.
[17] Kremer A,Louis JV,Jaworski T,et al.GSK3 and alzheimer's disease: facts and fiction[J].Front Mol Neurosci,2011,4:17.
[18] Drives"misfolding" XA.In protein amyloid fiber formation[J].Amyloid,2007,14(2):119-131.
[19] Vetrivel KS,Thinakaran G.Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments[J].Neurology,2006,66(2 Suppl 1):S69-S73.
[20] Janson J,Laedtke T,Parisi JE,et al.Increased risk of type 2 diabetes in Alzheimer disease[J].Diabetes,2004,53(2):474-481.
[21] Oskarsson ME,Paulsson JF,Schultz SW,et al.In vivo seeding and cross-seeding of localized amyloidosis: a molecular Link between type 2 diabetes and Alzheimer disease[J].Am J Pathol,2015,185(3):834-846.
[22] Frölich L,Blum-Degen D,Bernstein HG,et al.Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease[J].J Neural Transm,1998,105(4/5):423-438.
[23] Frölich L,Blum-Degen D,Riederer P,et al.A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease[J].Ann N Y Acad Sci,1999,893:290-293.
[24] Steen E,Terry BM,Rivera EJ,et al.Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease is this type 3 diabetes? [J].J Alzheimer's Dis,2005,7(1):63-80.
[25] Craft S,Asthana S,Schellenberg G,et al.Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender[J].Neuroendocrinology,1999,70(2):146-152.
[26] Luchsinger JA,Tang MX,Shea S,et al.Hyperinsulinemia and risk of Alzheimer disease[J].Neurology,2004,63(7):1187-1192.
[27] Suzuki M,Umegaki H,Ieda S,et al.Factors associated ith cognitive impairment in elderly patients with dia-betes mellitus[J].J Am Geriatr Soc,2006,54(3):558-559.
[28] Festa A,D'agostino R,Tracy RP,et al.Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study[J].Diabetes,2002,51(4):1131-1137.
[29] Engelhart MJ,Geerlings MI,Meijer J,et al.Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study[J].Arch Neurol,2004,61(5):668-672.
[30] Rosenberg PB.Clinical aspects of inflammation in Alzheimer's disease[J].Int Rev Psychiatry,2005,17(6):503-514.
[31] Lavielle P,Talavera JO,Reynoso N,et al.Prevalence of cognitive impairment in recently diagnosed type 2 diabetes patients: are chronic inflammatory diseases responsible for cognitive decline?[J].PLoS One,2015,10(10):e0141325.
[32] Yang H,Jin X,Lam K,et al.Oxidative stress and diabetes mellitus[J].Clin Chem Lab Med,2011,49(11):1773-1782.
[33] Pratico D,Sung S.Lipid peroxidation and oxidative imbalance:early functional events in Alzheimer's disease.J Alzheimer's Dis,2004,6(2):171-175.
[34] Clark TA,Lee HP,Rolston RK,et al.Oxidative stress and its implications for future treatments and management of alzheimer disease[J].Int J Biomed Sci,2010,6(3):225-227.
[35] Orth M, Schapira A. Mitochondria and degenerative disorders[J]. Am J Med Genet,2001,106(1): 27-36.
[36] Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited[J].Arterioscler Thromb Vasc Biol,2004,24(5): 816-823.
[37] Mahboobi H,Golmirzaei J,Gan SH,et al.Humanin: a possible linkage between Alzheimer's disease and type 2 diabetes[J].CNS Neurol Disord Drug Targets,2014,13(3):543-552.
[38] Hotamisligil GS,Erbay E.Nutrient sensing and inflammation in metabolic diseases[J].Nat Rev Immunol,2008,8(12):923-934.
[39] Kahn SE,Hull RL,Utzschneider KM.Mechanisms linking obesity to insulin resistance and type 2 diabetes[J].Nature,2006,444(7121):840-846.
[40] Anstey KJ,Cherbuin N,Budge M,et al.Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies[J].Obes Rev,2011,12(5):e426-e437.
[41] Gustafson D,Rothenberg E,Blennow K,et al.An 18-year follow-up of overweight and risk of Alzheimer disease[J].Arch Intern Med,2003,163(13):1524-1528.
[42] Razay G,Vreugdenhil A,Wilcock G.The metabolic syndrome and Alzheimer disease[J].Arch Neurol,2007,64(1):93-96.
[43] Takeuchi M,Yamagishi S.Alternative routes for the formation of glyceraldehyde-derived AGEs(TAGE)in vivo[J].Med Hypotheses,2004,63(3):453-455.
[44] Singh VP,Bali A,Singh N,et al.Advanced glycation end products and diabetic complications[J].Korean Journal of Physiology & Pharmacology,2014,18(1):1-14.
[45] Farrer LA,Cupples LA,Haines JL,et al.Effects of age,sex,and ethnicity on the association between apolipoprotein E genotype andAlzheimer disease:a meta-analysis[J].JAMA,1997,278(16):1349-1356.
[46] Malek-Ahmadi M,Beach T,Obradov A,et al.Increased alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE ε.4 carrier status[J].Curr Alzheimer Res,2013,10(6):654-659.
[47] Petanceska SS,Gandy S.The phosphatidylinositol 3-kinase inhibitor wortmannin alters the metabolism of the Alzheimer's amyloid precursor protein[J].J Neurochem,1999,73(6):2316-2320.
[48] Akter K,Lanza E,Martin SA,et al.Diabetes mellitus and Alzheimer's disease:shared pathology and treatment? [J].Br J Clin Pharmacol,2011,71(3):365-376.
[49] Lei P,Wu WH,Li RW,et al.Prevention and promotion effects of apolipoprotein E4 on amylin aggregation[J].Biochem Biophys Res Commun,2008,368(2):414-418.
[50] Fern ndez-Gamba A,Leal MC,Morelli L,et al.Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease[J].Curr Pharm Des,2009,15(31):3644-3655.
[51] Wyss-Coray T,Lin C,Yan F,et al.TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice[J].Nat Med,2001,7(5):612-618.
[52] Flanders KC,Ren RF,Lippa CF.Transforming growth factor-betas in neurodegenerative disease[J].Prog Neurobiol,1998,54(1):71-85.
[53] Tesseur I,Zou K,Esposito L,et al.Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology[J].J Clin Invest,2006,116(11):3060-3069.
[54] Mittal K,Mani RJ,Katare DP.Type 3 diabetes: cross talk between differentially regulated proteins of type 2 diabetes mellitus and alzheimer's disease[J].Sci Rep,2016,6(25589):25589.
[55] Costes S,Butler PC.Insulin-degrading enzyme inhibition, a novel therapy for type 2 diabetes?[J].Cell Metab,2014,20(2):201-203.
[56] Tang WJ.Targeting insulin-degrading enzyme to treat type 2 diabetes mellitus,Trends Endocrinol[J].Metab,27(1):24-34.
[57] Zhu B,Jiang RY,Yang C,et al.Adenosine monophosphate activated protein kinase activation mediates the leptin-induced attenuation of cognitive impairment in a streptozotocin-induced ratmodel[J].Exp Ther Med,2015,9(5):1998-2002.
[58] Cummings JL.Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations[J].Am J Geriatr Psychiatry,2003,11(2):131-145.